PsO Pipeline Update: Icotrokinra, an Oral IL-23 Blocker, Looks Good in Topline Phase 3 Data
Protagonist Therapeutics, Inc.’s oral icotrokinra (JNJ-2113, formerly PN-235),performed well in two Phase 3 ICONIC studies. Icotrokinra is the first-in-class targeted oral peptide that selectively blocks the interleukin (IL)-23 receptor, in individuals 12 years of age and older with moderate to severe plaque psoriasis. Protagonist Therapeutics and Johnson & Johnson have a license and collaboration agreement […]